Merit Ester Cudkowicz
#164,334
Most Influential Person Now
Merit Ester Cudkowicz's AcademicInfluence.com Rankings
Merit Ester Cudkowiczengineering Degrees
Engineering
#7209
World Rank
#8573
Historical Rank
Biomedical Engineering
#708
World Rank
#720
Historical Rank
Merit Ester Cudkowiczbiology Degrees
Biology
#13221
World Rank
#16754
Historical Rank
Neuroscience
#2277
World Rank
#2339
Historical Rank
Download Badge
Engineering Biology
Merit Ester Cudkowicz's Degrees
- Masters Biomedical Engineering Stanford University
- Bachelors Biomedical Engineering Stanford University
Why Is Merit Ester Cudkowicz Influential?
(Suggest an Edit or Addition)Merit Ester Cudkowicz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gait variability and basal ganglia disorders: Stride‐to‐stride variations of gait cycle timing in parkinson's disease and Huntington's disease (1998) (832)
- Altered fractal dynamics of gait: reduced stride-interval correlations with aging and Huntington's disease. (1997) (818)
- Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. (2014) (545)
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (2013) (522)
- Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. (2000) (432)
- Genome-wide Analyses Identify KIF5A as a Novel ALS Gene (2018) (414)
- Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. (2012) (404)
- Rate of functional decline in Huntington’s disease (2000) (332)
- Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice (2005) (318)
- Increased oxidative damage to DNA in ALS patients. (2000) (313)
- Evidence for more widespread cerebral pathology in early HD (2003) (287)
- Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice (2015) (274)
- Trial of celecoxib in amyotrophic lateral sclerosis (2006) (271)
- A clinical trial of creatine in ALS (2004) (267)
- Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS (2014) (262)
- Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis (2011) (259)
- Increased CSF F2-isoprostane concentration in probable AD (1999) (241)
- Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (2020) (227)
- Natural history of infantile‐onset spinal muscular atrophy (2017) (218)
- Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis (2005) (216)
- Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial (2014) (214)
- Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial (2013) (214)
- Identification of potential CSF biomarkers in ALS (2006) (210)
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. (2014) (205)
- Prospective study of military service and mortality from ALS (2005) (200)
- Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease (2003) (200)
- A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis (2003) (199)
- Degeneration of pyramidal projection neurons in Huntington's disease cortex (1990) (197)
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial (2010) (182)
- Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28 (2015) (180)
- Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression (2014) (180)
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis (2018) (179)
- The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis (2011) (167)
- Prospective study of cigarette smoking and amyotrophic lateral sclerosis. (2004) (160)
- Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial (2014) (156)
- Vitamin E intake and risk of amyotrophic lateral sclerosis (2005) (156)
- Clozapine and risperidone treatment of psychosis in Parkinson's disease. (2000) (156)
- Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS (2005) (153)
- Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) (2014) (151)
- Metabolomic analysis and signatures in motor neuron disease (2005) (150)
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (2020) (139)
- Phase 2 study of sodium phenylbutyrate in ALS (2009) (138)
- The PRO-ACT database (2014) (136)
- Riluzole therapy in Huntington's disease (HD) (1999) (128)
- Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models (2018) (125)
- Transcranial magnetic stimulation of the brain: guidelines for pain treatment research (2015) (124)
- Functional outcome measures as clinical trial endpoints in ALS (2004) (121)
- Transplantation of spinal cord–derived neural stem cells for ALS (2016) (118)
- Phase II/III randomized trial of TCH346 in patients with ALS (2007) (114)
- Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics (2010) (113)
- Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. (2006) (113)
- Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate (2008) (109)
- Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS) (2006) (108)
- Emerging targets and treatments in amyotrophic lateral sclerosis (2011) (107)
- Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis (2008) (105)
- A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease (2013) (103)
- Improving clinical trial outcomes in amyotrophic lateral sclerosis (2020) (103)
- SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. (2020) (99)
- The use of statistical MUNE in a multicenter clinical trial (2004) (99)
- Uric acid levels predict survival in men with amyotrophic lateral sclerosis (2012) (98)
- Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study (2016) (97)
- Cocaine-associated cerebral vasculitis. (1995) (97)
- Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (2013) (97)
- Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials (2007) (96)
- Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives (2005) (94)
- Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice (2009) (93)
- SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. (2013) (92)
- A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2017) (92)
- The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials (2013) (91)
- Expanded autologous regulatory T-lymphocyte infusions in ALS (2018) (91)
- Neuroprotective agents for clinical trials in ALS (2006) (87)
- Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects (2010) (87)
- Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial (2014) (85)
- Clinical significance in the change of decline in ALSFRS-R (2010) (84)
- Biochemical alterations associated with ALS (2012) (82)
- Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS (2012) (82)
- Motor, cognitive, and functional declines contribute to a single progressive factor in early HD (2017) (79)
- Coenzyme Q treatment of neurodegenerative diseases of aging. (2007) (79)
- Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics (2014) (78)
- ALS drug development: Reflections from the past and a way forward (2008) (78)
- A futility study of minocycline in Huntington's disease (2010) (77)
- Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. (2010) (75)
- Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS (2018) (75)
- The ALS Patient Care Database: Insights into End-of-Life Care in ALS (2001) (74)
- Toward more efficient clinical trials for amyotrophic lateral sclerosis (2010) (74)
- Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS (2015) (73)
- Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. (2006) (71)
- How common are ALS plateaus and reversals? (2016) (70)
- Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis (2016) (69)
- The natural history of ALS is changing: Improved survival (2009) (65)
- NurOwn, phase 2, randomized, clinical trial in patients with ALS (2019) (64)
- Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial (2017) (64)
- A randomized trial of mexiletine in ALS (2016) (64)
- Comparison of incremental with multipoint MUNE methods in transgenic ALS mice (2002) (62)
- Measures and markers in Amyotrophic Lateral Sclerosis (2004) (61)
- A High-Density Genome-Wide Association Screen of Sporadic ALS in US Veterans (2012) (61)
- Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis (2020) (58)
- Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. (2016) (54)
- Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis (2006) (54)
- Defining SOD1 ALS natural history to guide therapeutic clinical trial design (2016) (53)
- Arimoclomol: a potential therapy under development for ALS (2009) (53)
- Serum Ferritin and Metal Levels as Risk Factors for Amyotrophic Lateral Sclerosis (2008) (52)
- Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. (2020) (52)
- A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. (2013) (49)
- Thromboembolic Complications of Intravenous Immunoglobulin Treatment (2004) (49)
- Defining survival as an outcome measure in amyotrophic lateral sclerosis. (2009) (48)
- Outcome measures in amyotrophic lateral sclerosis clinical trials. (2014) (46)
- Revised statistical motor unit number estimation in the Celecoxib/ALS trial (2007) (46)
- A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS (2014) (46)
- Depression in amyotrophic lateral sclerosis (2011) (45)
- Neuroprotective agents for clinical trials in ALS: a systematic assessment. (2006) (44)
- Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach (2018) (44)
- A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis (2018) (43)
- Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS? (2015) (42)
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (2022) (42)
- A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis (2010) (41)
- Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis (2003) (41)
- Long‐term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS (2018) (40)
- Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS (2014) (39)
- Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities (2020) (39)
- Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in ρ0 cells (2003) (38)
- Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis (2012) (38)
- Respiratory measures in amyotrophic lateral sclerosis (2018) (37)
- Design of phase II ALS clinical trials (2008) (37)
- Neuroprotective agents target molecular mechanisms of disease in ALS. (2015) (37)
- Translating preclinical insights into effective human trials in ALS. (2006) (36)
- Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? (2015) (36)
- Scrutinizing enrollment in ALS clinical trials: Room for improvement? (2008) (36)
- Lyme disease serology in amyotrophic lateral sclerosis (2009) (35)
- Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines (2020) (35)
- 7‐T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosis (2013) (35)
- Analysis of start-up, retention, and adherence in ALS clinical trials (2013) (35)
- A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis (2019) (35)
- Job-related formaldehyde exposure and ALS mortality in the USA (2015) (34)
- Therapy development for ALS: Lessons learned and path forward (2008) (34)
- Race/ethnicity, socioeconomic status, and ALS mortality in the United States (2016) (34)
- Military Service and Amyotrophic Lateral Sclerosis in a Population-based Cohort (2015) (34)
- THE RELATIONSHIP BETWEEN GAIT CHANGES AND FALLS (1997) (33)
- Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics (2013) (32)
- Quantitative strength testing in ALS clinical trials (2016) (32)
- New considerations in the design of clinical trials for amyotrophic lateral sclerosis. (2011) (31)
- Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS (2008) (31)
- Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutations (2001) (31)
- Increased incidence of deep venous thrombosis in ALS (2007) (30)
- Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double‐blind crossover trial (2018) (29)
- Developing multidisciplinary clinics for neuromuscular care and research (2017) (29)
- Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis (2007) (29)
- Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS (2020) (29)
- Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: A preliminary safety and pharmacokinetic study (1997) (29)
- Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies (2006) (28)
- Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open‐Access ALS clinical trials database (2018) (28)
- Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity (2002) (27)
- Imaging of glia activation in people with primary lateral sclerosis (2017) (27)
- Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials (2012) (27)
- Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis (2011) (27)
- Understanding the use of NIV in ALS: results of an international ALS specialist survey (2018) (26)
- An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis (2018) (26)
- Pre‐morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis (2015) (26)
- Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis (2019) (25)
- Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. (2012) (24)
- Is it too soon for Mesenchymal Stem Cell trials in people with ALS? (2008) (23)
- Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis (2018) (23)
- Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers (2019) (22)
- A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis (2021) (22)
- A pilot trial of RNS60 in amyotrophic lateral sclerosis (2018) (22)
- Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development (2021) (21)
- An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis (1996) (21)
- Serum urate at trial entry and ALS progression in EMPOWER (2017) (20)
- Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis (2011) (20)
- Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis (2011) (20)
- Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection (2016) (19)
- Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients (2021) (19)
- Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis (2008) (19)
- VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics (2018) (19)
- Clinical Trials in Amyotrophic Lateral Sclerosis: The Tenuous Past and the Promising Future (2005) (18)
- Locked in, but not out? (2014) (17)
- Minocycline for patients with ALS (2008) (17)
- Urate Levels Predict Survival in ALS: Analysis of the Expanded PRO-ACT Database (2017) (17)
- Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis (2018) (17)
- IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis (2019) (17)
- PARVALBUMIN IMMUNOREACTIVE NEURONS ARE RESISTANT TO DEGENERATION IN HUNTINGTONʼS DISEASE CEREBRAL CORTEX: 252 (1990) (17)
- Addressing Heterogeneity in Als Clinical Trials. (2020) (17)
- Membranous nephropathy in a patient with renal cell carcinoma. (1991) (16)
- Fixed dynamometry is more sensitive than vital capacity or ALS rating scale (2017) (16)
- Lithium therapy in ALS (2008) (16)
- Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery (2007) (16)
- Risk factors for suicidality in Huntington disease (2019) (16)
- Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis (2014) (15)
- Trimethoprim and sulfonamide-associated meningoencephalitis with MRI correlates (1996) (15)
- The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis. (1999) (15)
- Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial (2022) (15)
- Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients (2020) (14)
- Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss (2021) (14)
- Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis (2017) (14)
- Predicting success: Optimizing phase II ALS trials for the transition to phase III (2014) (13)
- Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). (2017) (13)
- Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS (2018) (13)
- Opportunities for improving therapy development in ALS (2014) (13)
- Seeking a measure of clinically meaningful change in ALS (2014) (12)
- Biomarkers for amyotrophic lateral sclerosis (2006) (12)
- Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population (2016) (12)
- Histogenesis and cell lineage analysis of medulloblastomas (1989) (12)
- STAGE 3 Clinical Trial of Ceftriaxone in Subjects with ALS (S36.001) (2013) (12)
- Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial (2021) (11)
- Developing normalized strength scores for neuromuscular research (2013) (11)
- Proposed BioRepository platform solution for the ALS research community (2011) (11)
- What does body mass index measure in amyotrophic lateral sclerosis and why should we care? (2012) (10)
- Cortical Hyperexcitability in Amyotrophic Lateral Sclerosis: C9orf72 Repeats. (2015) (10)
- Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform (2022) (10)
- ALSUntangled: Introducing The Table of Evidence (2015) (10)
- Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis (2021) (10)
- Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes (2022) (10)
- Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis (2021) (9)
- Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients (2009) (9)
- Improving the responsiveness of rating scales (2004) (9)
- Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis (2020) (9)
- Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial (2021) (9)
- Oral Repeated-Dose Toxicity Studies of Coenzyme Q10 in Beagle Dogs (2012) (8)
- Principles of neuroepidemiology (2001) (8)
- Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post‐mortem motor cortex and cerebrospinal fluid (2021) (7)
- Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA! (2018) (7)
- Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice (2006) (7)
- A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS (2022) (7)
- Preclinical rodent toxicity studies for long term use of ceftriaxone (2015) (7)
- Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance. (2009) (7)
- Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol (2022) (7)
- Genome-Encoded Cytoplasmic Double-Stranded RNAs, Found in C9ORF72 ALS-FTD Brain, Provoke Propagated Neuronal Death (2018) (7)
- Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. (2020) (6)
- IPLEX and the Telephone Game: The difficulty in separating myth from reality on the internet (2009) (6)
- Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial (2020) (6)
- Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial (2020) (6)
- Alterations in gait dynamics in health and disease: are they independent of gait speed? (1999) (6)
- Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment (2021) (6)
- Disease course unaltered by a single intracisternal injection of BMP‐7 in ALS mice (2002) (6)
- ALSUntangled No. 26: Lunasin (2014) (6)
- Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses (2022) (5)
- The Role of Environmental Toxins in Amyotrophic Lateral Sclerosis Risk. (2016) (5)
- Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS (2013) (5)
- Maximum voluntary isometric contraction (MVIC) (2004) (5)
- MODULATION OF CSF miRNAs IN ALS PHASE 2 STUDY PARTICIPANTS TREATED WITH MSC-NTF CELLS (NUROWN®) (S25.005) (2018) (4)
- IL6 receptor 358 Ala variant and trans-signaling are disease modi fi ers in amyotrophic lateral sclerosis (4)
- Safety and efficacy of transplantation of nurown (autologous mesenchymal stromal cells secreting neurotrophic factors) in patients with ALS: A phase 2 randomized double blind placebo controlled trial (2017) (4)
- Disease burden in upper motor neuron syndromes: a survey of patient perspectives. (2014) (4)
- Results of a Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients with Familial ALS Due to SOD1 Gene Mutations (S25.001) (2012) (4)
- Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. (2015) (4)
- ALSUntangled 38: L-serine (2017) (4)
- ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors (2020) (4)
- Preface: promoting research in PLS: current knowledge and future challenges (2020) (4)
- Opinion and Special Articles: Challenges and opportunities in defining career identity in academic neurology (2018) (4)
- Regulatory Approval in ALS; When Is a Single Study Enough? (2022) (3)
- Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis (2022) (3)
- Thrombopoietin is ineffective in a mouse model of motor neuron disease (2008) (3)
- An expanded access protocol of RT001 in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor (2022) (3)
- Antibody Response to HML‐2 May Be Protective in Amyotrophic Lateral Sclerosis (2022) (3)
- REMOVED: Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS (2015) (3)
- Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data (2022) (3)
- 290 - In vivo modulation of neurotrophic and inflammatory factors in the CSF of ALS patients treated with NurOwn (MSC NTF cells) (2017) (3)
- ALSUntangled #64: butyrates (2022) (3)
- NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains (S38.002) (2018) (3)
- Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? (2006) (3)
- Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD (2021) (3)
- Clinical Trial Testing Lithium in ALS Terminates Early for Futility (2011) (3)
- Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis (2010) (3)
- Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial (2017) (2)
- Sodium Phenylbutyrate-Taurursodiol for ALS. Reply. (2020) (2)
- Neurologic Disorders in Women (1997) (2)
- Profound Muscle Weakness and Pain after One Dose of Actonel (2009) (2)
- NN 102/SPRINT-MS Phase II Trial of Ibudilast in Progressive MS: Baseline Characteristics (P7.214) (2015) (2)
- Abstracts from the ASENT 2010 annual meeting March 4–6, 2010 (2010) (2)
- Is erythropoietin a potential therapy for amyotrophic lateral sclerosis? (2007) (2)
- The EMPOWER Study (2012) (2)
- ALS/SURV: a modification of the CAFS statistic (2019) (2)
- Apolipoprotein B-100-mediated motor neuron degeneration in sporadic amyotrophic lateral sclerosis (2022) (2)
- A Phase 2 Study of Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (S50.004) (2015) (2)
- Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review. (2022) (2)
- Tofersen, a SOD1 Antisense Oligonucleotide in Participants with ALS – Results From a Multiple Dose Study (657) (2020) (2)
- North East ALS Study Group (2004) (2)
- Reply: To PMID 25900666. (2015) (2)
- Noninvasive ventilation use by patients enrolled in VITALITY-ALS (2021) (1)
- Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis (2021) (1)
- Predictors of Outcome in Amyotrophic Lateral Sclerosis (P2.076) (2014) (1)
- Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial (2021) (1)
- Efficacy of Dexpramipexole in Amyotrophic Lateral Sclerosis: Data from the Phase III EMPOWER Trial (PL02.004) (2013) (1)
- Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS) (2020) (1)
- Vital capacity: High test-retest variability in ALS patients with bulbar weakness (2017) (1)
- The ALS Stratification Prize-Using the Power of Big Data and Crowdsourcing for Catalyzing Breakthroughs in Amyotrophic Lateral Sclerosis (ALS) (P5.102) (2016) (1)
- Regional Pattern of Symptom Spread in Amyotrophic Lateral Sclerosis (ALS) (P06.130) (2013) (1)
- Detection of serum reverse transcriptase activity in amyotrophic lateral sclerosis patients and unaffected relatives (2004) (1)
- ALSUntangled #63: ketogenic diets (2021) (1)
- Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles (2021) (1)
- ALSUntangled No. 36: Accilion (2017) (1)
- Theme 09 - CLINICAL TRIALS AND TRIAL DESIGN (2021) (1)
- A Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod In Patients with Amyotrophic Lateral Sclerosis (ALS) (P7.067) (2015) (1)
- Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results (2022) (1)
- Progression to Clinically Meaningful Changes in ALSFRS-R Bulbar and Fine Motor Domains is Faster in Bulbar Onset and in Limb Onset Amyotrophic Lateral Sclerosis Patients Respectively (P5.051) (2015) (1)
- ALS Enters the World of Big Data: Initial Description of and Results from the PRO-ACT Platform (P07.064) (2013) (1)
- The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis (2022) (1)
- ALS and Unproven Treatments: What Should Patients and Physicians Do? (2008) (1)
- CSF markers in amyotrophic lateral sclerosis (2010) (1)
- Dexpramipexole Effects on Functional Decline in ALS Patients in a Phase II Study: Subgroup Analysis of Demographic and Clinical Characteristics (P04.149) (2012) (1)
- Melatonin and Other Neuroprotective Agents Target Molecular Mechanisms of Disease in Amyotrophic Lateral Sclerosis (2016) (1)
- Abstract #5: A Phase I, Dosage-Escalation Study of Creatine Monohydrate in Subjects with Amyotrophic Lateral Sclerosis (2010) (1)
- Reply (2015) (0)
- Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. (2017) (0)
- The Northeast ALS Consortium (NEALS) Upper Motor Neuron Disease (UMND) Registry (P5.076) (2014) (0)
- Magnetic Resonance Spectroscopy and Survival Prediction in ALS (2007) (0)
- Author Index (1997) (0)
- NeuroBANK™: Integrated Clinical Data Repository Platform as a Model for Clinical Research (P07.072) (2013) (0)
- Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trial Management (P1.334) (2014) (0)
- Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis (2023) (0)
- ALS Biomarker Discovery Using SOMAscan™ Multiplex Proteomic Technology (2012) (0)
- Safety and Tolerability of Dexpramipexole for the Treatment of ALS: Results from the Randomized, Double-Blind, Placebo-Controlled Trial, EMPOWER (PL02.003) (2013) (0)
- CLT-01 A systematic review of enrichment strategies for current clinical trials in ALS (2018) (0)
- 806 Intraspinal and Systemic Stem Cell Transplantation Delays Onset, Improves Survival in Transgenic Amyotrophic Lateral Sclerosis Mice (2001) (0)
- Cerebrospinal fluid levels of F2‐isoprostanes in patients with neurodegenerative diseases (1999) (0)
- Patient Centricity and Big Data in Rare Neurological Diseases: Reality or Bright Future? (P4.092) (2016) (0)
- Microglial Activation in People with Amyotrophic Lateral Sclerosis (P06.132) (2013) (0)
- Robert H. Ackerman, MD, MPH (1935–2018) (2019) (0)
- ALSUntangled No. 29: MitoQ (2015) (0)
- ALSUntangled No. 35: Hyperbaric Oxygen Therapy* (2016) (0)
- Baseline Variables Associated with Functional Decline in 2CARE: A Randomized Clinical Trial in Huntington's Disease. (2020) (0)
- Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS? (2015) (0)
- Academic Neurology and the COVID-19 Pandemic (2022) (0)
- Does a Modifying Factor Affect Outcome in Inherited ALS (2001) (0)
- Correction to: ‘Seeking a measure of clinically meaningful change in ALS’ (2014) (0)
- Opportunities for improving therapy development in ALS LUCIE BRUIjN (2014) (0)
- Preventing Amyotrophic Lateral Sclerosis Before It Starts: When to Intervene? (2022) (0)
- ALSUntangled #67: rituximab. (2022) (0)
- Clinical Trials in Neurology: Amyotrophic Lateral Sclerosis (2012) (0)
- NeuroBANK™ and Global Unique Patient Identifier Allow for Secure Collaboration, Data Aggregation and Sharing (S46.007) (2014) (0)
- P87 STRUCTURAL BRAIN CORRELATES OF COGNITIVE AND BEHAVIOURAL IMPAIRMENT IN MND (2015) (0)
- Measures and markers in Amyotrophic Lateral Sclerosis (2004) (0)
- Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach (2019) (0)
- Understanding the use of noninvasive ventilation in the treatment of amyotrophic lateral sclerosis in the US and Europe: results of an international physician survey (P5.071) (2017) (0)
- Platform for Clinical Trials Data Integration and Sharing as a Unique Industry, Academic, and Foundation Collaboration Resource in ALS Research (P01.091) (2012) (0)
- WHAT IS NEXT IN ALS CLINICAL TRIALS? Author's reply (2008) (0)
- A single-center , phase 1 , open label , dosage-escalation study of creatine monohydrate in subject with amyotrophic lateral sclerosis (2009) (0)
- Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? (2015) (0)
- Inserting MS Word Document into RTF Output and Creating Customized Table of Contents Using SAS ® and VBA Macro (2014) (0)
- Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial (2017) (0)
- Reply (1997) (0)
- THEME 9 CLINICAL TRIALS AND TRIAL DESIGN CLT-01 RNS60 in ALS: Expanded Access Program (0)
- Mean plasma ozanezumab concentration-time profiles following single (A) or two (B) IV infusions of ozanezumab. (2014) (0)
- ALS Clinical Research Learning Institutes: Empowering PALS to Be Research Ambassadors (P1.340) (2014) (0)
- Partitioning the genetic architecture of amyotrophic lateral sclerosis (2018) (0)
- 5-nitro-gamma-tocopherol is a biomarker for nitrative stress in human neurological disease (2000) (0)
- Therapeutic trials in amyotrophic lateral sclerosis: past, present and future (2021) (0)
- Would riluzole be efficacious in the new ALS trial design? – Authors' reply (2010) (0)
- Free-Radical Toxicity in Amyotrophic Lateral Sclerosis (2018) (0)
- Mexiletine for the treatment of muscle cramps in ALS: a randomized double-blind crossover trial (S38.004) (2017) (0)
- Current Understanding of Glutamate and Neurotoxicity in ALS (2003) (0)
- Development and Evaluation of a Simulation-Based Algorithm to Optimize the Planning of Interim Analyses for Clinical Trials in ALS. (2023) (0)
- Minocycline for ALS (2008) (0)
- Versatile Polymer-Based Nanocarriers for Targeted Therapy and Immunomodulation (2021) (0)
- 7 T MRI of the pathological spinal cord (2012) (0)
- Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS). (2023) (0)
- A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis (CT.004) (2018) (0)
- Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Concept to Implementation (P04.245) (2013) (0)
- Identification of a Unique miRNA Signature in CD14+/CD16- Blood-Monocytes in ALS Subjects Identical to That Observed in SOD Mice (P05.167) (2012) (0)
- Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial (2017) (0)
- Delays in Diagnosing Amyotrophic Lateral Sclerosis (P03.174) (2012) (0)
- Stem Cell Transplantation for ALS (2008) (0)
- Evaluating the Effect of Sodium Phenylbutyrate and Taurursodiol on Survival Outcomes in Amyotrophic Lateral Sclerosis Using a Propensity Score–Matched Cohort From the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database (S33.005) (2023) (0)
- Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations (P8-8.004) (2023) (0)
- AAN Practice Parameter: Updated Guideline on ALS Treatment and Management (2009) (0)
- SELECTIVE SPARING OF NEUROPEPTIDE-Y NEURONS IN HUNTINGTONʼS DISEASE CEREBRAL CORTEX: 93 (1989) (0)
- A chromosomal conformation signature for a priori prediction of ALS progression subtypes (2018) (0)
- Genome-wide Analyses Id entify KIF 5 A as a Novel ALS Gene Highlights (2018) (0)
- PRO-ACE: Global Collaborative Ecosystem in a Post-PRO-ACT Era (P4.6-006) (2019) (0)
- Transcranial magnetic stimulation of the brain: guidelines for pain treatment research (0)
- Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2016) (0)
- Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. (2017) (0)
- Title Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis : a randomised , double-blind , placebo-controlled phase 2 trial (2014) (0)
- Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004) (2023) (0)
- ALSUntangled #68: ozone therapy. (2022) (0)
- Military service and amyotrophic lateral sclerosis in a US population-based cohort (S36.005) (2015) (0)
- Primary and secondary progressive MS subjects in clinical trials: Are they similar? (P2.059) (2017) (0)
- Survival and Disease Progression in SOD1 Familial ALS in North America (P3.185) (2016) (0)
- Urate Levels Predict Disease Progression and Survival in Amyotrophic Lateral Sclerosis (ALS). (P6.100) (2015) (0)
- The EMPOWER Study: Design, Methodology and Baseline Features of the First Phase III Clinical Trial of Dexpramipexole for Patients with ALS (S25.004) (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Merit Ester Cudkowicz?
Merit Ester Cudkowicz is affiliated with the following schools:
